Giacomo Cartenì
University of Naples Federico II
CancerInternal medicineSurgeryOncologyAdverse effectExpanded accessChemotherapyNeutropeniaRenal cell carcinomaCarcinomaTolerabilitySunitinibEverolimusNivolumabProstate cancerNephrectomyFluorouracilPopulationIn patientPhases of clinical researchMedicineGastroenterology
186Publications
39H-index
5,007Citations
Publications 182
Newest
#1Sara Elena RebuzziH-Index: 10
#2Alessio SignoriH-Index: 32
Last. Giacomo CartenìH-Index: 39
view all 20 authors...
Source
#1Alessandra Mosca (University of Eastern Piedmont)H-Index: 16
#2Ugo De GiorgiH-Index: 56
Last. Camillo Porta (UNIPV: University of Pavia)H-Index: 70
view all 12 authors...
OBJECTIVE Despite the current immunotherapy era, VEGFR inhibitors maintain effectiveness in metastatic renal cell cancer. Real-world data concerning pazopanib are limited. The aim of this study is to add information about efficacy and safety of pazopanib as first-line treatment in metastatic renal cell cancer patients not enrolled into clinical trials. METHODS Retrospective analysis (the PAMERIT study) of first-line pazopanib in real-world metastatic renal cell cancer patients among 39 Centers i...
Source
#1Matteo SantoniH-Index: 48
#2Francesco MassariH-Index: 45
Last. Angelo MartignettiH-Index: 9
view all 20 authors...
We analyzed the clinical and pathological features of renal cell carcinoma (RCC) patients treated with cabozantinib stratified by body mass index (BMI). We retrospectively collected data from 16 worldwide centers involved in the treatment of RCC. Overall survival (OS) and progression-free survival (PFS) were analyzed using Kaplan-Meier curves. Cox proportional models were used at univariate and multivariate analyses. We collected data from 224 patients with advanced RCC receiving cabozantinib as...
Source
Currently, conventional treatments for metastatic RCC (mRCC) include immune-based combination regimens and/or targeted therapies, the latter mainly acting on angiogenesis, a key element of the process of tumor growth and spread. Although these agents proved able to improve patients' outcomes, drug resistance and disease progression are still experienced by a substantial number of VEGFR-TKIs-treated mRCC patients. Following the inhibition of the VEGF/VEGFRs axis, two strategies have emerged: eith...
Source
#1Margaret OttavianoH-Index: 9
#2Marcello CurviettoH-Index: 10
Last. ScitoH-Index: 1
view all 95 authors...
Background The coronavirus disease 2019 (COVID-19) pandemic has overwhelmed the health systems worldwide. Data regarding the impact of COVID-19 on cancer patients (CPs) undergoing or candidate for immune checkpoint inhibitors (ICIs) are lacking. We depicted the practice and adaptations in the management of patients with solid tumors eligible or receiving ICIs during the COVID-19 pandemic, with a special focus on Campania region. Methods This survey (25 questions), promoted by the young section o...
Source
#1Umberto BassoH-Index: 43
#2Federico PaolieriH-Index: 3
Last. L. FratinoH-Index: 2
view all 20 authors...
Source
#2Carmela BarbatoH-Index: 2
Last. Giacomo CartenìH-Index: 39
view all 10 authors...
Chemotherapy-induced peripheral neuropathy (CIPN) is the most frequently reported adverse effect of oxaliplatin. In this study, we set out to evaluate the role of the panaceo-micro-activation (PMA) zeolite in the reduction of the incidence of CIPN and hematological and liver toxicity. The possible impact of the PMA-zeolite as an adjuvant therapeutic agent is based on its detoxification properties toward agents promoting the development of neuropathy (e.g., ammonium – recognized as a neurotoxic a...
Source
#1Editta BaldiniH-Index: 23
#2Alice LunghiH-Index: 2
Last. Diana GiannarelliH-Index: 71
view all 22 authors...
Abstract Objectives The incidence of any and of severe-grade immune-related adverse events (irAEs) with second-line nivolumab monotherapy is 31-65% and 2-5% respectively. While potentially serious and even fatal, in the absence of an appropriate therapy, such events might be indicators of the activation of the immune system and, potentially, of efficacy. Materials and Methods We collected the records of 1,959 non-small-cell lung cancer (NSCLC) patients treated with nivolumab in the Italian expan...
Source
#1Matteo SantoniH-Index: 48
#2Daniel Y.C. Heng (TBCC: Tom Baker Cancer Centre)H-Index: 13
Last. Nicola BattelliH-Index: 18
view all 49 authors...
Cabozantinib is approved for the treatment of renal cell carcinoma (RCC). However, prognostic factors are still lacking in this context. The aim of this study was to evaluate prognostic factors in RCC patients treated with second- or third-line cabozantinib. A multicenter retrospective real-world study was conducted, involving 32 worldwide centers. A total of 237 patients with histologically confirmed clear-cell and non-clear-cell RCC who received cabozantinib as second- or third-line therapy fo...
Source
This multi-institutional retrospective real life study was conducted in 22 Italian Oncology Centers and evaluated the role of Axitinib in second line treatment in not selected mRCC patients. 148 mRCC patients were evaluated. According to Heng score 15.5%, 60.1% and 24.4% of patients were at poor risk, intermediate and favorable risk, respectively. PFS, OS, DCR and ORR were 7.14 months, 15.5 months, 70.6% and 16.6%, respectively. The duration of prior sunitinib treatment correlated with a longer ...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.